TerrAscend (TSNDF) Income towards Parent Company (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Income towards Parent Company of -$1.2 million for Q1 2026, up 74.48% year-over-year from -$673434.6 in Q1 2025, and down 128.59% quarter-over-quarter from $4.1 million in Q4 2025.
TerrAscend (TSNDF) Income towards Parent Company (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Income towards Parent Company for 6 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company rose 74.48% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$53.4 million (down 5.3% YoY), while the FY2025 annual figure was -$56.8 million, down 9.78% from the prior year.
- Income towards Parent Company fell to -$1.2 million in Q1 2026 per TSNDF's latest filing, from $4.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $4.1 million in Q4 2025 and bottomed at -$54.7 million in Q4 2023.
- Historically, Income towards Parent Company has averaged -$12.0 million across 5 years, with a median of -$4.6 million in 2025.
- On a YoY basis, Income towards Parent Company climbed as much as 110.13% in 2025 and fell as far as 86977.08% in 2025.
- TerrAscend's Income towards Parent Company stood at -$10.6 million in 2022, then plunged by 417.02% to -$54.7 million in 2023, then gained by 25.74% to -$40.6 million in 2024, then jumped by 110.13% to $4.1 million in 2025, then plunged by 128.59% to -$1.2 million in 2026.
- Business Quant data shows TSNDF's Income towards Parent Company at -$1.2 million in Q1 2026, $4.1 million in Q4 2025, and -$14.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | TerrAscend | 197.99 Mn | 155.88 Mn | 36.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | -1.18 Mn |
| Dec 31, 2025 | 4.11 Mn |
| Sep 30, 2025 | -14.65 Mn |
| Jun 30, 2025 | -41.70 Mn |
| Mar 31, 2025 | -4.60 Mn |
| Dec 31, 2024 | -40.59 Mn |
| Sep 30, 2024 | -5.58 Mn |
| Jun 30, 2024 | 48,000.00 |
| Mar 31, 2024 | -14.85 Mn |
| Dec 31, 2023 | -54.66 Mn |
| Sep 30, 2023 | -232,000.00 |
| Jun 30, 2023 | -621,000.00 |
| Mar 31, 2023 | -3.59 Mn |
| Dec 31, 2022 | -10.57 Mn |
| Sep 30, 2022 | -10.42 Mn |
| Jun 30, 2022 | -2.70 Mn |
| Mar 31, 2022 | -2.26 Mn |
| Dec 31, 2021 | 2.35 Mn |
| Sep 30, 2021 | 55.84 Mn |